Literature DB >> 6870880

Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats.

M L Blank, M N Hall, E A Cress, F Snyder.   

Abstract

We have partially characterized the properties of a specific acetylhydrolase in plasma from spontaneous hypertensive rats. This enzyme inactivates 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a lipid involved in platelet aggregating, hypotensive, and allergic responses) by removal of the acetate group. The extent of acetate hydrolysis was linear with both time and protein concentration, and the enzyme had an apparent Km of 2.5 microM and a Vmax of 2.6 nmol/min/mg protein. As with an intracellular acetylhydrolase previously characterized by us, the plasma activity was not affected by addition of phosphatidylcholine, EDTA, or Ca2+. However, in contrast to the acetylhydrolase activity in the rat kidney soluble fraction, the plasma activity was associated with a higher molecular weight protein resolved on a Sepharose 6B column and the plasma acetylhydrolase was not inhibited by treatment with trypsin, pronase, or subtilisin. We also compared the acetylhydrolase activity in plasma of age-matched spontaneous hypertensive rats and their normotensive controls, and found approximately 20% higher levels of activity in plasma from the hypertensive animals (P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6870880     DOI: 10.1016/0006-291x(83)91778-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

1.  Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.

Authors:  Y Yang; E M Nemoto; S A K Harvey; V M Subbotin; C R Gandhi
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

2.  Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage.

Authors:  Y Hirashima; S Nakamura; S Endo; N Kuwayama; Y Naruse; A Takaku
Journal:  Neurochem Res       Date:  1997-10       Impact factor: 3.996

3.  Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis.

Authors:  Yong-Ping Yang; Xue-Mei Ma; Chun-Ping Wang; Jun Han; Yin-Ying Lu; Yi Xiang; Shu-Hui Su; Yong-Yi Feng
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

Review 4.  Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Christina Chrysohoou; Smaragdi Antonopoulou
Journal:  Curr Heart Fail Rep       Date:  2013-06

5.  Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2.

Authors:  K Satoh; T Imaizumi; Y Kawamura; H Yoshida; M Hiramoto; S Takamatsu; M Takamatsu
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

6.  Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor.

Authors:  G Ambrosio; A Oriente; C Napoli; G Palumbo; P Chiariello; G Marone; M Condorelli; M Chiariello; M Triggiani
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

7.  A sensitive and specific radioimmunoassay for platelet-activating factor.

Authors:  C Wang; H H Tai
Journal:  Lipids       Date:  1992-03       Impact factor: 1.880

8.  The degradation of platelet-activating factor by high-density lipoprotein in rat plasma. Effect of ethynyloestradiol administration.

Authors:  P H Pritchard
Journal:  Biochem J       Date:  1987-09-15       Impact factor: 3.857

9.  Human platelets release a paf-acether: acetylhydrolase similar to that in plasma.

Authors:  R Korth; J Bidault; R Palmantier; J Benveniste; E Ninio
Journal:  Lipids       Date:  1993-03       Impact factor: 1.880

10.  Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients.

Authors:  Juergen Graessler; Dominik Schwudke; Peter E H Schwarz; Ronny Herzog; Andrej Shevchenko; Stefan R Bornstein
Journal:  PLoS One       Date:  2009-07-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.